GLP‐1 RA and atrial fibrillation in the cardiovascular outcome trials
Sign Up to like & getrecommendations! Published in 2021 at "Diabetes/Metabolism Research and Reviews"
DOI: 10.1002/dmrr.3436
Abstract: INTRODUCTION Type 2 diabetes is known as an independent risk factor for atrial fibrillation. While glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated multiple cardiovascular effects, including decrease in blood pressure and total cholesterol, their… read more here.
Keywords: atrial fibrillation; individuals type; fibrillation; cardiovascular outcome ... See more keywords
Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors: Are They All the Same? A Narrative Review of Cardiovascular Outcome Trials
Sign Up to like & getrecommendations! Published in 2020 at "Diabetes Therapy"
DOI: 10.1007/s13300-020-00951-6
Abstract: Clinically important improvements in cardiovascular risk factors and adverse cardiovascular, heart failure and renal outcomes have been observed in numerous cardiovascular outcome trials (CVOTs) investigating the use of sodium-glucose co-transporter 2 (SGLT2) inhibitors over the last… read more here.
Keywords: sglt2 inhibitors; sodium glucose; glucose transporter; cardiovascular outcome ... See more keywords
Unravelling the utility of modern sulfonylureas from cardiovascular outcome trials and landmark trials: expert opinion from an international panel
Sign Up to like & getrecommendations! Published in 2020 at "Indian Heart Journal"
DOI: 10.1016/j.ihj.2020.01.001
Abstract: Aim The primary objective of this review is to develop practice-based expert group opinions on the cardiovascular (CV) safety and utility of modern sulfonylureas (SUs) in cardiovascular outcome trials (CVOTs). Background The United States Food… read more here.
Keywords: utility modern; modern sulfonylureas; modern sus; cardiovascular outcome ... See more keywords
CARDIOVASCULAR EFFICACY OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS: A META-ANALYSIS OF CARDIOVASCULAR OUTCOME TRIALS
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Hypertension"
DOI: 10.1097/01.hjh.0000837316.89812.46
Abstract: Objective: Type 2 diabetes mellitus (T2DM) has gradually evolved as a metabolic pandemic. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are currently considered an attractive treatment option for diabetic patients with established atherosclerotic cardiovascular disease or for… read more here.
Keywords: receptor agonists; cardiovascular outcome; outcome; peptide receptor ... See more keywords
Cardiovascular outcome trials in type 2 diabetes: A nurse practitioner perspective
Sign Up to like & getrecommendations! Published in 2018 at "Journal of the American Association of Nurse Practitioners"
DOI: 10.1097/jxx.0000000000000126
Abstract: ABSTRACT To provide an overview of cardiovascular outcome trials (CVOT) with once-weekly glucagon-like peptide-1 receptor agonists (GLP-1RAs), and other recent CVOTs, and to discuss the implications for the management of patients with type 2 diabetes… read more here.
Keywords: cardiovascular outcome; lowering drugs; type diabetes; outcome trials ... See more keywords
Sodium‐glucose co‐transporter‐2 inhibitors and cardiovascular outcome studies in people with type 2 diabetes: From efficacy to effectiveness
Sign Up to like & getrecommendations! Published in 2018 at "Diabetes"
DOI: 10.1111/dom.13142
Abstract: Cardiovascular disease remains the main cause of morbidity and mortality in people with diabetes, and is also the largest contributor to healthcare costs in this population(1). read more here.
Keywords: sodium glucose; glucose transporter; inhibitors cardiovascular; outcome studies ... See more keywords
Long‐term cardiovascular outcome of renal transplant recipients after early conversion to everolimus compared to calcineurin inhibition: results from the randomized controlled MECANO trial
Sign Up to like & getrecommendations! Published in 2018 at "Transplant International"
DOI: 10.1111/tri.13322
Abstract: Long‐term data on cardiovascular (CV) outcome of renal transplant recipients (RTR) on mTOR‐i (mammalian Target Of Rapamycin‐inhibitors) are scarce. In a sub‐study of the MECANO trial we investigated changes in intima media thickness (IMT), CV… read more here.
Keywords: outcome renal; long term; cardiovascular outcome; mecano trial ... See more keywords
Serum neutrophil gelatinase-associated lipocalin has an advantage over serum cystatin C and glomerular filtration rate in prediction of adverse cardiovascular outcome in patients with ST-segment elevation myocardial infarction
Sign Up to like & getrecommendations! Published in 2017 at "BMC Cardiovascular Disorders"
DOI: 10.1186/s12872-017-0514-5
Abstract: BackgroundThe aim of this study was to assess significance of serum neutrophil gelatinase-associated lipocalin (sNGAL) and cystatin C (sCC) in prediction of adverse cardiovascular outcome after ST-segment elevation myocardial infarction (STEMI).MethodsWe recruited 357 consecutive patients… read more here.
Keywords: cardiovascular outcome; prediction adverse; adverse cardiovascular; serum ... See more keywords
Improvement of glycemic control and reduction of major cardiovascular events in 18 cardiovascular outcome trials: an updated meta-regression
Sign Up to like & getrecommendations! Published in 2021 at "Cardiovascular Diabetology"
DOI: 10.1186/s12933-021-01401-8
Abstract: Background Besides providing reassurance about cardiovascular (CV) safety of newer diabetes drugs, cardiovascular outcome trials (CVOTs) have also shown encouraging benefits on some CV endpoints. The contribution of the better glycemic control in the reduction… read more here.
Keywords: reduction; mace; cardiovascular outcome; outcome trials ... See more keywords
Comment on Ferrannini and Rosenstock. Clinical Translation of Cardiovascular Outcome Trials in Type 2 Diabetes: Is There More or Is There Less Than Meets the Eye? Diabetes Care 2021;44:641–646
Sign Up to like & getrecommendations! Published in 2021 at "Diabetes Care"
DOI: 10.2337/dc21-0518
Abstract: I read with great interest the recent Perspective by Ferrannini and Rosenstock (1), which provides thoughtful insight on the interpretation of the numerous recent cardiovascular outcome trials (CVOT) in the field of type 2 diabetes.… read more here.
Keywords: cardiovascular outcome; leader; type diabetes; outcome trials ... See more keywords
Insulin Therapy and Cardiovascular Outcome Trials (Cvots): Any Harm, Anytime?
Sign Up to like & getrecommendations! Published in 2018 at "Genetics and Molecular Research"
DOI: 10.31031/gmr.2018.01.000513
Abstract: The therapeutic management of diabetes may on its own increase the risk of cardiovascular (CV) risk markers – directly or indirectly – through their pharmacological actions (e.g. side effects as hypoglycaemia), or some metabolic changes… read more here.
Keywords: therapy cardiovascular; insulin therapy; cardiovascular outcome; outcome trials ... See more keywords